48.36 USD
+0.04 (+0.08%)
48.2069 USD
-0.15 (-0.32%)
Overall SNY gets a fundamental rating of 6 out of 10. We evaluated SNY against 192 industry peers in the Pharmaceuticals industry. SNY scores excellent on profitability, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on SNY. Finally SNY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year SNY was profitable.
In the past year SNY had a positive cash flow from operations.
In the past 5 years SNY has always been profitable.
In the past 5 years SNY always reported a positive cash flow from operatings.
1.2 Ratios
SNY has a better Return On Assets (11.05%) than 92.19% of its industry peers.
SNY's Return On Equity of 19.73% is amongst the best of the industry. SNY outperforms 90.10% of its industry peers.
SNY has a better Return On Invested Capital (13.84%) than 93.23% of its industry peers.
SNY had an Average Return On Invested Capital over the past 3 years of 7.31%. This is significantly below the industry average of 12.85%.
The 3 year average ROIC (7.31%) for SNY is below the current ROIC(13.84%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROIC | 13.84% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
SNY has a Profit Margin of 20.35%. This is amongst the best in the industry. SNY outperforms 91.15% of its industry peers.
In the last couple of years the Profit Margin of SNY has grown nicely.
SNY has a better Operating Margin (23.59%) than 90.63% of its industry peers.
SNY's Operating Margin has improved in the last couple of years.
SNY's Gross Margin of 71.70% is fine compared to the rest of the industry. SNY outperforms 78.13% of its industry peers.
In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), SNY is creating some value.
The number of shares outstanding for SNY remains at a similar level compared to 1 year ago.
Compared to 5 years ago, SNY has about the same amount of shares outstanding.
Compared to 1 year ago, SNY has an improved debt to assets ratio.
2.2 Solvency
SNY has a debt to FCF ratio of 2.21. This is a good value and a sign of high solvency as SNY would need 2.21 years to pay back of all of its debts.
The Debt to FCF ratio of SNY (2.21) is better than 93.23% of its industry peers.
SNY has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
SNY has a Debt to Equity ratio (0.21) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Altman-Z | N/A |
ROIC/WACC1.79
WACC7.75%
2.3 Liquidity
SNY has a Current Ratio of 1.27. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.27, SNY is doing worse than 77.60% of the companies in the same industry.
A Quick Ratio of 0.94 indicates that SNY may have some problems paying its short term obligations.
SNY has a Quick ratio of 0.94. This is in the lower half of the industry: SNY underperforms 79.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
SNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.35%.
SNY shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.10% yearly.
The Revenue has been growing slightly by 2.56% in the past year.
The Revenue has been growing slightly by 3.31% on average over the past years.
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
3.2 Future
The Earnings Per Share is expected to grow by 7.11% on average over the next years.
The Revenue is expected to grow by 4.55% on average over the next years.
EPS Next Y3.02%
EPS Next 2Y5.77%
EPS Next 3Y5.98%
EPS Next 5Y7.11%
Revenue Next Year0.64%
Revenue Next 2Y3.51%
Revenue Next 3Y4.42%
Revenue Next 5Y4.55%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 10.77 indicates a reasonable valuation of SNY.
Based on the Price/Earnings ratio, SNY is valued cheaply inside the industry as 90.63% of the companies are valued more expensively.
SNY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.59.
With a Price/Forward Earnings ratio of 9.52, the valuation of SNY can be described as very reasonable.
Based on the Price/Forward Earnings ratio, SNY is valued cheaper than 89.06% of the companies in the same industry.
SNY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.03.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.77 | ||
| Fwd PE | 9.52 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 97.40% of the companies listed in the same industry.
SNY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SNY is cheaper than 90.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.9 | ||
| EV/EBITDA | 5.44 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SNY does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of SNY may justify a higher PE ratio.
PEG (NY)3.57
PEG (5Y)2.11
EPS Next 2Y5.77%
EPS Next 3Y5.98%
5. Dividend
5.1 Amount
SNY has a Yearly Dividend Yield of 4.77%, which is a nice return.
SNY's Dividend Yield is rather good when compared to the industry average which is at 0.45. SNY pays more dividend than 97.92% of the companies in the same industry.
SNY's Dividend Yield is rather good when compared to the S&P500 average which is at 1.87.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.77% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.30%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of SNY decreased in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
SNY pays out 34.82% of its income as dividend. This is a sustainable payout ratio.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP34.82%
EPS Next 2Y5.77%
EPS Next 3Y5.98%
48.36
+0.04 (+0.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.31%
Inst Owner Change-5.34%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap117.47B
Revenue(TTM)66.91B
Net Income(TTM)13.81B
Analysts81.38
Price TargetN/A
Short Float %0.29%
Short Ratio2.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.77% |
Yearly Dividend2.22
Dividend Growth(5Y)4.3%
DP34.82%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.86%
Min EPS beat(2)-2.29%
Max EPS beat(2)6.02%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-2.29%
Max EPS beat(4)14.5%
EPS beat(8)4
Avg EPS beat(8)2.17%
EPS beat(12)7
Avg EPS beat(12)2.71%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)9.26%
Revenue beat(16)8
Avg Revenue beat(16)21.08%
PT rev (1m)0.6%
PT rev (3m)-3.97%
EPS NQ rev (1m)-0.61%
EPS NQ rev (3m)-4.38%
EPS NY rev (1m)0.24%
EPS NY rev (3m)-1.11%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-1.69%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)0.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.77 | ||
| Fwd PE | 9.52 | ||
| P/S | 1.47 | ||
| P/FCF | 9.9 | ||
| P/OCF | 8.76 | ||
| P/B | 1.42 | ||
| P/tB | 10.72 | ||
| EV/EBITDA | 5.44 |
EPS(TTM)4.49
EY9.28%
EPS(NY)5.08
Fwd EY10.5%
FCF(TTM)4.89
FCFY10.11%
OCF(TTM)5.52
OCFY11.42%
SpS32.95
BVpS33.97
TBVpS4.51
PEG (NY)3.57
PEG (5Y)2.11
Graham Number58.58
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROCE | 16.7% | ||
| ROIC | 13.84% | ||
| ROICexc | 16.48% | ||
| ROICexgc | 66.95% | ||
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% | ||
| FCFM | 14.83% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexgc growth 3Y-13.63%
ROICexgc growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Debt/EBITDA | 0.75 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 58.05% | ||
| Profit Quality | 72.91% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | N/A |
F-Score7
WACC7.75%
ROIC/WACC1.79
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
EPS Next Y3.02%
EPS Next 2Y5.77%
EPS Next 3Y5.98%
EPS Next 5Y7.11%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
Revenue Next Year0.64%
Revenue Next 2Y3.51%
Revenue Next 3Y4.42%
Revenue Next 5Y4.55%
EBIT growth 1Y15.64%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year29.46%
EBIT Next 3Y13.42%
EBIT Next 5Y11.66%
FCF growth 1Y24.23%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y10.87%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%
SANOFI-ADR / SNY FAQ
What is the fundamental rating for SNY stock?
ChartMill assigns a fundamental rating of 6 / 10 to SNY.
What is the valuation status for SNY stock?
ChartMill assigns a valuation rating of 8 / 10 to SANOFI-ADR (SNY). This can be considered as Undervalued.
How profitable is SANOFI-ADR (SNY) stock?
SANOFI-ADR (SNY) has a profitability rating of 8 / 10.
What is the valuation of SANOFI-ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SANOFI-ADR (SNY) is 10.77 and the Price/Book (PB) ratio is 1.42.
Can you provide the financial health for SNY stock?
The financial health rating of SANOFI-ADR (SNY) is 4 / 10.